After signing up, you'll start to receive regular news updates from us.
Odyssey Thera Announces a Major Multi-Year Collaboration with Pfizer
Complete the form below to unlock access to ALL audio articles.
Odyssey Thera, Inc. has announced that it has entered into an alliance with Pfizer Inc. to utilize Odyssey Thera's Protein-fragment Complementation Assay (PCA) technology to evaluate the selectivity of Pfizer compounds.
Under the terms of the multi-year agreement, Odyssey Thera will receive an upfront payment, research and capital expenditure funding, and success based milestone payments.
Odyssey Thera's patented PCA technology measures pathway activity within living cells and can be applied to signaling pathways relevant to diverse therapeutic areas.
By probing changes in the intricate biochemical networks of living cells following compound application, Odyssey Thera can identify on-target and off-pathway activities of drugs and lead compounds.
In May of 2005, Odyssey Thera announced its second agreement with Pfizer to profile compounds across Odyssey Thera's panel of cell-based assays.
The success of those efforts has led to the current expanded collaboration, which will focus on large numbers of Pfizer chemical leads and drug candidates from multiple therapeutic areas.
Odyssey Thera's proprietary PCAs, and other assays based on high-throughput automated microscopy, will be used to measure changes in the cellular signaling networks in response to Pfizer compounds.
In addition, the collaboration involves the development of tools and strategies to aid in the selection of pharmaceutical candidates that may have favorable safety and selectivity profiles, as predicted by PCA technology and other assays, for further evaluation.
"Drugs act on proteins within pathways and networks in living cells, and our analyses uniquely exploit this fact," said Dr. John K. Westwick, Odyssey Thera President and CSO.
"We have engineered the world's largest collection of pathway-based assays, along with an infrastructure to enable the rapid analysis of large numbers of test compounds," Dr. Westwick continued.
"These capabilities allow us to identify the most promising drug candidates at an early stage in the discovery process."
"The significant expansion of our collaboration with Pfizer validates our approach to defining compound activities within living cells, and we look forward to working closely with Pfizer to further develop these powerful tools."
